The notices it replaced
Its page was not saved, so the notices it replaced are not known.
Who won it before
Competing awards, new and renewals, since FY2014, under this notice and the notices it replaced.
- Past awards
- 66
- 66 new
- Median first-year cost
- $410,067
- $29,893,386 in all
- Institutions
- 46
- 65 contact PIs
- Patents
- 14
- from 8 funded projects
Awards by fiscal year
0
0
32
34
0
0
0
0
0
0
0
0
0
14151617181920212223242526
Fiscal years 2014 to 2026.
Most frequent institutions
- UNIVERSITY OF TX MD ANDERSON CAN CTR5
- DANA-FARBER CANCER INST4
- STANFORD UNIVERSITY3
- CEDARS-SINAI MEDICAL CENTER2
- ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI2
and 41 other institutions
Most frequent study sections
- Special Emphasis Panel (ZCA1 RPRB-M (M5))5
- Special Emphasis Panel (ZCA1 RTRB-E (M2))5
- Special Emphasis Panel (ZCA1 RPRB-F (M1))4
- Special Emphasis Panel (ZCA1 RTRB-R (J1))4
- Special Emphasis Panel (ZCA1 RPRB-0 (J1))3
and 24 other study sections
| FY | Project | PIs | Institution | First-year cost | Study section |
|---|---|---|---|---|---|
| FY2017 | (PQ6) Radiogenomics of colorectal polyps to assess benign proliferative vs. premalignant states.1R01CA220004-01 | Grady, William MalloryHalberg, Richard BrottPickhardt, Perry | FRED HUTCHINSON CANCER RESEARCH CENTER, WA | First-year cost $739,041 | Study section ZCA1 |
| FY2017 | (PQ7)Multi-scale Analysis of Tumor Microenvironment Heterogeneity1R01CA208735-01A1 | Felsher, Dean W | STANFORD UNIVERSITY, CA | First-year cost $729,393 | Study section ZCA1 |
| FY2017 | (PQ8) Genetically faithful murine models for studying disease progression in chronic lymphocytic leukemia1R01CA216273-01 | Wang, LiliWu, Catherine Ju-Ying | DANA-FARBER CANCER INST, MA | First-year cost $701,924 | Study section ZCA1 |
| FY2017 | (PQ3) Cellular and Molecular Mechanisms Driving Myeloid Compartment Variation in Human Triple Negative Breast Cancer1R01CA219880-01 | Palucka, Anna Karolina | JACKSON LABORATORY, ME | First-year cost $697,539 | Study section ZCA1 |
| FY2017 | (PQ#3) Novel tumor intrinsic PD-L1 signals direct tumor immune cell infiltration1R01CA205965-01A1 | Curiel, Tyler J. | UNIVERSITY OF TEXAS HLTH SCIENCE CENTER, TX | First-year cost $650,815 | Study section ZCA1 |
| FY2017 | (PQ3) Immune epigenetic biomarkers of bladder cancer outcomes1R01CA216265-01 | Christensen, Brock Clarke | DARTMOUTH COLLEGE, NH | First-year cost $632,860 | Study section ZCA1 |
| FY2017 | (7) Novel imaging devices for measurement and control of tumor microenvironments1R01CA216248-01 | Castracane, JamesCondeelis, John SEntenberg, David | ALBERT EINSTEIN COLLEGE OF MEDICINE, INC, NY | First-year cost $565,675 | Study section ZCA1 |
| FY2017 | (PQ9) Directed and unbiased studies of synaptic injuries as sequelae of radiotherapy: mapping, sex-dependence, and reversal1R01CA219667-01 | Duman, Joseph G | BAYLOR COLLEGE OF MEDICINE, TX | First-year cost $554,770 | Study section ZCA1 |
| FY2017 | Immune biological differences between Triple Negative Breast Cancer in African American and non-African American women and potential immunotherapy opportunities to improve treatment outcome1R01CA219647-01 | Pusztai, Lajos | YALE UNIVERSITY, CT | First-year cost $552,594 | Study section ZCA1 |
| FY2017 | (PQ9)Mechanistic Role of APE1 and BER in chemotherapy-induced peripheral neuropathy1R01CA205166-01A1 | Kelley, Mark R. | INDIANA UNIVERSITY INDIANAPOLIS, IN | First-year cost $536,312 | Study section ZCA1 |
| FY2017 | Obesity Increases Breast Cancer Penetrance in BRCA Mutation Carriers: A Role for Local and Systemic Factors1R01CA215797-01 | Brown, Kristy A.Dannenberg, Andrew Jess | WEILL MEDICAL COLL OF CORNELL UNIV, NY | First-year cost $515,275 | Study section ZCA1 |
| FY2017 | (9) Therapeutic strategies to mitigate toxicities of platinum-based therapeutics1R01CA215802-01 | Pabla, NavjotSparreboom, Alexander | OHIO STATE UNIVERSITY, OH | First-year cost $503,309 | Study section ZCA1 |
| FY2017 | (PQ9)A redox-mediated mechanism of chemotherapy-induced cognitive impairment1R01CA217934-01 | Bondada, SubbaraoButterfield, D. AllanSt Clair, Daret K | UNIVERSITY OF KENTUCKY, KY | First-year cost $455,149 | Study section ZCA1 |
| FY2017 | (PQ#9) Promoting Axon Stability to Prevent Therapy-induced Peripheral Neuropathy1R01CA219866-01 | Diantonio, AaronMilbrandt, Jeffrey D | WASHINGTON UNIVERSITY, MO | First-year cost $445,407 | Study section ZCA1 |
| FY2017 | (PQ 9) Dysregulation of epidermal MMP-13 as cause of paclitaxel-induced peripheral neuropathy1R01CA215973-01 | Rieger, Sandra | MOUNT DESERT ISLAND BIOLOGICAL LAB, ME | First-year cost $443,022 | Study section ZCA1 |
| FY2017 | (PQ1) Progenitor cell malfunction, mutations and changes in microenvironment: A dynamic risk spectrum for cancer evolution1R01CA219893-01 | Ghosh, MoumitaMiller, York E | NATIONAL JEWISH HEALTH, CO | First-year cost $442,614 | Study section ZCA1 |
| FY2017 | Role of microbiota in therapy to ovarian cancer1R01CA216234-01 | Randall, Troy D | UNIVERSITY OF ALABAMA AT BIRMINGHAM, AL | First-year cost $426,139 | Study section ZCA1 |
| FY2017 | RNF128 Regulation of TP53 in Barrett's Progression1R01CA215596-01 | Beer, David GeorgeRay, Dipankar | UNIVERSITY OF MICHIGAN AT ANN ARBOR, MI | First-year cost $414,063 | Study section ZCA1 |
| FY2017 | Exploiting mitochondrial heteroplasmy for cancer chemotherapy1R01CA219859-01 | Sabatini, David M. | WHITEHEAD INSTITUTE FOR BIOMEDICAL RES, MA | First-year cost $390,000 | Study section ZCA1 |
| FY2017 | AN IMAGING-BASED APPROACH TO UNDERSTAND AND PREDICT CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY1R01CA208623-01A1 | Berezin, Mikhail Y. | WASHINGTON UNIVERSITY, MO | First-year cost $389,684 | Study section ZCA1 |
| FY2017 | Deciphering How Esco2 Loss Acts as a Penetrance Modifier1R01CA216108-01 | Parant, John M | UNIVERSITY OF ALABAMA AT BIRMINGHAM, AL | First-year cost $359,477 | Study section ZCA1 |
| FY2017 | Role of Senescent Cells in Radiation-induced Pulmonary Fibrosis1R01CA219836-01 | Zhou, Daohong | UNIV OF ARKANSAS FOR MED SCIS, AR | First-year cost $354,709 | Study section ZCA1 |
| FY2017 | Impact of the Microbiome on the Efficacy of Radiation Therapy1R01CA220000-01 | Shiao, Stephen L. | CEDARS-SINAI MEDICAL CENTER, CA | First-year cost $350,000 | Study section ZCA1 |
| FY2017 | (PQ #10) Gut-brain interactions underlying chemotherapy-induced behavioral comorbidities1R01CA216290-01 | Pyter, Leah M | OHIO STATE UNIVERSITY, OH | First-year cost $338,903 | Study section ZCA1 |
| FY2017 | Targeted Payment Cuts to Reduce Unproven Care1R01CA208758-01A1 | Howard, David H | EMORY UNIVERSITY, GA | First-year cost $336,912 | Study section ZCA1 |
| FY2017 | Uncovering the Role of Colorectal Stem Cells on Disease Penetrance in Lynch Syndrome1R01CA219463-01 | Vilar Sanchez, Eduardo | UNIVERSITY OF TX MD ANDERSON CAN CTR, TX | First-year cost $330,675 | Study section ZCA1 |
| FY2017 | (PQ1) Identifying and targeting human glioblastoma migrating in the peritumoral niche1R01CA216054-01 | Hayden Gephart, Melanie | STANFORD UNIVERSITY, CA | First-year cost $324,411 | Study section ZCA1 |
| FY2017 | Mitochondrial Dynamics in Brain TumorInitiating Cells1R01CA208516-01A1 | Mears, Jason | CASE WESTERN RESERVE UNIVERSITY, OH | First-year cost $320,000 | Study section ZCA1 |
| FY2017 | (PQ5) Consequences of imbalanced mitophagy and mitochondrial biogenesis in cancer1R01CA216242-01 | Macleod, Kay F | UNIVERSITY OF CHICAGO, IL | First-year cost $318,277 | Study section ZCA1 |
| FY2017 | Effect of radiotherapy on dendritic cell subsets: implications for immunotherapy1R01CA219994-01 | Idoyaga, Juliana | STANFORD UNIVERSITY, CA | First-year cost $314,908 | Study section ZCA1 |
| FY2017 | Mechanisms that control the progression from premalignant lesions to adenocarcinomas in the lung1R01CA205165-01A1 | Galbiati, Ferruccio | UNIVERSITY OF PITTSBURGH AT PITTSBURGH, PA | First-year cost $310,250 | Study section ZCA1 |
| FY2017 | Targeting the Opioidergic and Adrenergic Systems to Control Breast Cancers1R01CA208632-01A1 | Sarkar, Dipak Kumar | RUTGERS, THE STATE UNIV OF N.J., NJ | First-year cost $310,000 | Study section ZCA1 |
| FY2017 | (PQ3) Disruption of immune surveillance by aneuploidy and aberrant MHCII expression1R01CA220009-01 | Carter, Hannah KathrynZanetti, Maurizio | UNIVERSITY OF CALIFORNIA, SAN DIEGO, CA | First-year cost $310,000 | Study section ZCA1 |
| FY2017 | Molecular Mechanisms Underlying Environmental Effects that Influence Penetrance in Lynch Syndrome-Associated Endometrial Cancer1R01CA216103-01 | Yates, Melinda S. | UNIVERSITY OF TX MD ANDERSON CAN CTR, TX | First-year cost $256,000 | Study section ZCA1 |
| FY2016 | Host factors, tumor microenvironment and survival in a multiethnic study of Hodgkin lymphoma patients1R01CA206019-01 | Cozen, Wendy | UNIVERSITY OF SOUTHERN CALIFORNIA, CA | First-year cost $735,600 | Study section ZCA1 |
| FY2016 | PQ1: Identification and characterization of genetic alterations for the progression of pre-neoplastic lung lesions by using novel PDx models and deep sequencing1R01CA206027-01 | Hoque, Mohammad ObaidulSidransky, David | JOHNS HOPKINS UNIVERSITY, MD | First-year cost $688,142 | Study section ZCA1 |
| FY2016 | (PQ#9)Targeting leaky ryanodine receptor (RyR2) to treat and prevent chemotherapy-associated cognitive dysfunction in patients with breast cancer.1R01CA206025-01 | Guise, Theresa AMarks, Andrew RobertTerrito, Paul Richard | INDIANA UNIVERSITY INDIANAPOLIS, IN | First-year cost $655,037 | Study section ZCA1 |
| FY2016 | Determinants of genetic penetrance in identical twins with breast cancer1R01CA208772-01 | Mack, Thomas McCulloch | UNIVERSITY OF SOUTHERN CALIFORNIA, CA | First-year cost $588,101 | Study section ZCA1 |
| FY2016 | Determinants of pancreatic cancer and malignant melanoma phenotypes in CDKN2A hereditary kindreds1R01CA208517-01 | Fernandez-Zapico, Martin ErnestoLi, HuPetersen, Gloria M. | MAYO CLINIC ROCHESTER, MN | First-year cost $578,620 | Study section ZCA1 |
| FY2016 | (PQ9) The role of Bclw (bcl2l2) in preventing chemotherapy induced neuropathy1R01CA205255-01 | Segal, Rosalind A. | DANA-FARBER CANCER INST, MA | First-year cost $577,463 | Study section ZCA1 |
| FY2016 | (PQ9) Characterization and prophylactic treatment of chemotherapy-induced long-term adverse sequelae1R01CA208634-01 | Jurecic, Roland | UNIVERSITY OF MIAMI SCHOOL OF MEDICINE, FL | First-year cost $560,277 | Study section ZCA1 |
| FY2016 | (PQ 9) Synaptic basis of deficits in attention and executive function following cranial radiation1R01CA208535-01 | Grosshans, David R | UNIVERSITY OF TX MD ANDERSON CAN CTR, TX | First-year cost $536,390 | Study section ZCA1 |
| FY2016 | (PQ7) In Vivo Cellular Optical Imaging of Esophageal Tumors and Microenvironment1R01CA205431-01 | Perelman, Lev T | BETH ISRAEL DEACONESS MEDICAL CENTER, MA | First-year cost $533,945 | Study section ZCA1 |
| FY2016 | (PQ3) The role of damaged DNA in inter-individual variation of tumor immunity1R01CA208756-01 | Hacohen, Nir | BROAD INSTITUTE, INC., MA | First-year cost $518,165 | Study section ZCA1 |
| FY2016 | (9) Biophysical Description of Age and Dose Dependent Changes to Dendritic Morphology that Impact Cognition following Radiation Cancer Therapy1R01CA208526-01 | Cucinotta, Francis A | UNIVERSITY OF NEVADA LAS VEGAS, NV | First-year cost $484,047 | Study section ZCA1 |
| FY2016 | (PQ6) Molecular Mechanisms Driving Benign to Malignant Transitions in Breast Cancer1R01CA205632-01 | Riegel, Anna Tate | GEORGETOWN UNIVERSITY, DC | First-year cost $469,489 | Study section ZCA1 |
| FY2016 | (PQ1) Characterization of Premalignant Fields in a Murine Model of Head and Neck and Esophageal Cancers1R01CA205258-01 | Gudas, Lorraine J | WEILL MEDICAL COLL OF CORNELL UNIV, NY | First-year cost $464,261 | Study section ZCA1 |
| FY2016 | (PQ1) Genomic characterization of mesenchymal stromal cells in Monoclonal Gammopathy of Undermined Significance (MGUS)1R01CA205954-01 | Ghobrial, Irene M. | DANA-FARBER CANCER INST, MA | First-year cost $438,499 | Study section ZCA1 |
| FY2016 | (PQ5) Mitochondria are endocellular symbionts that serve as targets for immune recognition1R01CA206012-01 | Facciabene, Andrea | UNIVERSITY OF PENNSYLVANIA, PA | First-year cost $417,457 | Study section ZCA1 |
| FY2016 | (PQ7) Quantitative in vivo optical imaging of tumor heterogeneity1R01CA205101-01 | Skala, Melissa Caroline | MORGRIDGE INSTITUTE FOR RESEARCH, INC., WI | First-year cost $406,070 | Study section ZCA1 |
| FY2016 | Mesenchymal Stem Cells to Repair Chemobrain1R01CA208371-01 | Heijnen, Cobi JKavelaars, Annemieke | UNIVERSITY OF TX MD ANDERSON CAN CTR, TX | First-year cost $402,051 | Study section ZCA1 |
| FY2016 | Cancer-Associated Fibroblasts Alter the Composition of B cells in Solid Malignancies1R01CA208753-01 | Orsulic, Sandra | CEDARS-SINAI MEDICAL CENTER, CA | First-year cost $400,313 | Study section ZCA1 |
| FY2016 | (PQ5) Investigation of intertumoral and intratumoral heterogeneity of mitochondrial apoptotic sensitivity1R01CA205967-01 | Letai, Anthony G | DANA-FARBER CANCER INST, MA | First-year cost $390,540 | Study section ZCA1 |
| FY2016 | (PQ5) Mitochondria in Leukemic Stem Cell Disease Progression1R01CA205975-01A1 | Ghaffari, Saghi | ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI, NY | First-year cost $386,619 | Study section ZCA1 |
| FY2016 | PQ 5 Exploring whole mitochondrial genome of screen detected pre-neoplastic lung lesions by novel approaches1R01CA208709-01 | Hoque, Mohammad ObaidulSidransky, David | JOHNS HOPKINS UNIVERSITY, MD | First-year cost $383,423 | Study section ZCA1 |
| FY2016 | (PQ11) Targeting STING in the context of chemoradiation therapy to overcome poor preexisting immunity in mouse models of pancreatic cancer.1R01CA208644-01 | Crittenden, Marka | PROVIDENCE PORTLAND MEDICAL CENTER, OR | First-year cost $377,438 | Study section ZCA1 |
| FY2016 | (PQ3) Immune Modulation of DNA Mismatch Repair in Colorectal Cancer1R01CA206010-01 | Carethers, John M | UNIVERSITY OF MICHIGAN AT ANN ARBOR, MI | First-year cost $369,639 | Study section ZCA1 |
| FY2016 | Genomics and Mechanisms of Esophageal Carcinogenesis1R01CA208711-01 | Sepulveda, Antonia Rogado | COLUMBIA UNIVERSITY HEALTH SCIENCES, NY | First-year cost $366,000 | Study section ZCA1 |
| FY2016 | (PQ9) Mitigation of chemotherapy induced peripheral neuropathy1R01CA206028-01 | Damaj, M. ImadGewirtz, David A. | VIRGINIA COMMONWEALTH UNIVERSITY, VA | First-year cost $363,112 | Study section ZCA1 |
| FY2016 | (PQ1) Progression of the airway field of injury to Kras mutant lung cancer1R01CA205608-01A1 | Kadara, HumamScheet, Paul A | UNIVERSITY OF TX MD ANDERSON CAN CTR, TX | First-year cost $360,634 | Study section ZCA1 |
| FY2016 | (PQ1) Epigenetic effects of the premalignant field1R01CA208620-01 | Terada, Lance S | UT SOUTHWESTERN MEDICAL CENTER, TX | First-year cost $357,464 | Study section ZCA1 |
| FY2016 | (PQ1) GUCY2C hormone loss translates APC-Beta-catenin mutations into epithelial transformation1R01CA206026-01 | Waldman, Scott A | THOMAS JEFFERSON UNIVERSITY, PA | First-year cost $356,850 | Study section ZCA1 |
| FY2016 | Developing a targeted chemoprevention strategy for Non-Small Cell Lung Cancer1R01CA208303-01 | Gomperts, Brigitte N | UNIVERSITY OF CALIFORNIA LOS ANGELES, CA | First-year cost $352,275 | Study section ZCA1 |
| FY2016 | (PQ5) Imaging mitochondrial heterogeneity in LKB1 mutant lung cancer1R01CA208642-01 | Shackelford, David B | UNIVERSITY OF CALIFORNIA LOS ANGELES, CA | First-year cost $352,275 | Study section ZCA1 |
| FY2016 | (PQ9) A novel mechanism of paclitaxel-induced peripheral neuropathy and potential treatment1R01CA208765-01 | Yang, Qing | UNIVERSITY OF TEXAS HLTH SCI CTR HOUSTON, TX | First-year cost $351,874 | Study section ZCA1 |
| FY2016 | (PQ5) Role of Mitochondrial Division in Cancer Biology1R01CA206005-01 | Chipuk, Jerry Edward | ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI, NY | First-year cost $351,209 | Study section ZCA1 |
Newest fiscal year first, then first-year cost.
Patents from its funded projects
14 patents name 8 of the 66 funded projects. The newest 5, by patent number.
- US 12,529,692 (opens the patent at USPTO, a PDF, in a new tab)LIVE CELL IMAGING DYNAMIC BH3 PROFILINGGranted January 20, 2026 to DANA-FARBER CANCER INSTITUTE, INC.R01CA205967 · DANA-FARBER CANCER INST, MA
- US 12,508,243 (opens the patent at USPTO, a PDF, in a new tab)COMPOSITIONS AND METHODS FOR TREATING CANCER AND IMPROVING EPITHELIAL HOMEOSTASISGranted December 30, 2025 to THE REGENTS OF THE UNIVERSITY OF CALIFORNIAR01CA208303 · UNIVERSITY OF CALIFORNIA LOS ANGELES, CA
- US 12,502,671 (opens the patent at USPTO, a PDF, in a new tab)SYSTEMS AND METHODS FOR CLASSIFYING T CELL ACTIVATION STATEGranted December 23, 2025 to Wisconsin Alumni Research FoundationR01CA205101 · MORGRIDGE INSTITUTE FOR RESEARCH, INC., WI
- US 12,441,775 (opens the patent at USPTO, a PDF, in a new tab)BCL-W Polypeptides and Mimetics for Treating or Preventing Chemotherapy-Induced Peripheral Neuropathy and Hearing LossGranted October 14, 2025 to Dana-Farber Cancer Institute, Inc. and President and Fellows of Harvard CollegeR01CA205255 · DANA-FARBER CANCER INST, MA
- US 12,441,722 (opens the patent at USPTO, a PDF, in a new tab)THERAPEUTIC AGENTS AND METHODS OF TREATMENTGranted October 14, 2025 to University of Florida Research Foundation, Inc.R01CA219836 · UNIV OF ARKANSAS FOR MED SCIS, AR
Each number opens the patent at USPTO, beside the project NIH ties it to and that project's institution. NIH ties a patent to a project, not to a year of its funding, and says its list is incomplete. The grant date and the owners are USPTO's: the organizations the patent names as assignees on the day it was granted. Source: United States Patent and Trademark Office, www.uspto.gov, which does not endorse ScienceDex.
Data: Grants.gov's daily extract and NIH's notice pages, award files and patents file, in ScienceGraph release conductgrants-2026-11-12-0.3.1. An award is listed only where NIH's own record names the notice, and a PI only by NIH's profile ID. Grants.gov and NIH do not endorse ScienceDex.